{
  "id": 11134729,
  "title": "#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity",
  "url": "https://urgent.news/2026/10/01/easd26-boehringers-weight-loss-candidate-trails-rivals-in-diabetes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T07:30:26.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/easd26-boehringer-weight-loss-candidate-trails-rivals-in-diabetes-and-obesity/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Boehringer Ingelheim's lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes. According to Endpoints News, this result trailed other candidates.\n\nIn comparison, Eli Lilly's investigational medication, a combination of eloralintide and tirzepatide, resulted in weight loss of up to 23.3% at the maximum dose, as reported by Medical Xpress. This study, presented at the European Association for the Study of Diabetes meeting in Milan, Italy, evaluated 367 adults with obesity or overweight and type 2 diabetes.\n\nThe study found substantial improvements in blood sugar control alongside the weight loss. Medical Xpress described eloralintide as a selective amylin receptor agonist and tirzepatide as a dual GIP/GLP-1 receptor agonist.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes",
        "url": "https://urgent.news/2026/09/30/easd26-lillys-amylin-zepbound-combo-posts-best-ever-weight-loss-in",
        "published": "2026-09-30T14:15:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}